HYL — Hyloris Pharmaceuticals SA Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual cashflow statement for Hyloris Pharmaceuticals SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-7.14	-11.6	-11.9	-15.4	-6.34
Depreciation
Non-Cash Items	1.89	0.769	0.666	0.041	0.206
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	0.101	-0.577	-1.98	2.18	-1.42
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-4.57	-11.3	-13	-12.8	-6.9
Capital Expenditures	-0.623	-1.06	-0.739	-0.75	-0.297
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-0.01	-2.01	-10.6	10.6	0.556
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-0.633	-3.08	-11.4	9.89	0.259
Financing Cash Flow Items	74.2	—	12.5	-0.012	0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	69.4	-0.062	7.84	-0.131	-0.168
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	64.2	-14.4	-16.6	-3.05	-6.81